These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26275855)

  • 1. Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics.
    Jacobs SA; Gibbs AC; Conk M; Yi F; Maguire D; Kane C; O'Neil KT
    Protein Eng Des Sel; 2015 Oct; 28(10):385-93. PubMed ID: 26275855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
    Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
    Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.
    Stork R; Müller D; Kontermann RE
    Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A.
    Unverdorben F; Färber-Schwarz A; Richter F; Hutt M; Kontermann RE
    Protein Eng Des Sel; 2012 Feb; 25(2):81-8. PubMed ID: 22238430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of novel FN3 domains with high stability by a consensus sequence approach.
    Jacobs SA; Diem MD; Luo J; Teplyakov A; Obmolova G; Malia T; Gilliland GL; O'Neil KT
    Protein Eng Des Sel; 2012 Mar; 25(3):107-17. PubMed ID: 22240293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-life extension using serum albumin-binding DARPin® domains.
    Steiner D; Merz FW; Sonderegger I; Gulotti-Georgieva M; Villemagne D; Phillips DJ; Forrer P; Stumpp MT; Zitt C; Binz HK
    Protein Eng Des Sel; 2017 Sep; 30(9):583-591. PubMed ID: 29088432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and characterization of a long-acting ciliary neurotrophic factor via genetically fused with an albumin-binding domain.
    Xu L; Zhang C; Liu L; Zhang Y; Wang Q; Wang J; Liu Y; Su Z
    Protein Expr Purif; 2017 Nov; 139():14-20. PubMed ID: 28711730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-affinity binding to staphylococcal protein A by an engineered dimeric Affibody molecule.
    Lindborg M; Dubnovitsky A; Olesen K; Björkman T; Abrahmsén L; Feldwisch J; Härd T
    Protein Eng Des Sel; 2013 Oct; 26(10):635-44. PubMed ID: 23924760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.
    Metzner HJ; Weimer T; Kronthaler U; Lang W; Schulte S
    Thromb Haemost; 2009 Oct; 102(4):634-44. PubMed ID: 19806248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of an optimized scaffold for affibody molecules.
    Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
    J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing the stability and solubility of the glucocorticoid receptor ligand-binding domain by high-throughput library screening.
    Seitz T; Thoma R; Schoch GA; Stihle M; Benz J; D'Arcy B; Wiget A; Ruf A; Hennig M; Sterner R
    J Mol Biol; 2010 Nov; 403(4):562-77. PubMed ID: 20850457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion.
    Deyev SM; Oroujeni M; Garousi J; Gräslund T; Li R; Rosly AHB; Orlova A; Konovalova E; Schulga A; Vorobyeva A; Tolmachev V
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
    Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
    J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein.
    Gapizov SS; Petrovskaya LE; Shingarova LN; Kryukova EA; Boldyreva EF; Lukashev EP; Yakimov SA; Svirshchevskaya EV; Dolgikh DA; Kirpichnikov MP
    Biotechnol Appl Biochem; 2019 Jul; 66(4):617-625. PubMed ID: 31140614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo.
    Ren Z; Zhao J; Cao X; Wang F
    Protein Expr Purif; 2022 Dec; 200():106147. PubMed ID: 35917982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid isolation of high-affinity protein binding peptides using bacterial display.
    Bessette PH; Rice JJ; Daugherty PS
    Protein Eng Des Sel; 2004 Oct; 17(10):731-9. PubMed ID: 15531628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of new modular nanotransporters with albumin-binding domain.
    Khramtsov YV; Ulasov AV; Tsvetkova AD; Rosenkranz AA; Georgiev GP; Sobolev AS
    Dokl Biochem Biophys; 2017 Jan; 472(1):81-83. PubMed ID: 28421445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
    Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
    Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.